[1]胡绍福,朱 江,张志敏,等.阿加曲班治疗急性缺血性卒中的疗效及对血清Gal-3、CTRP9表达的影响[J].医学信息,2023,36(23):103-106.[doi:10.3969/j.issn.1006-1959.2023.23.026]
　HU Shao-fu,ZHU Jiang,ZHANG Zhi-min,et al.Efficacy of Argatroban in the Treatment of Acute Ischemic Stroke and its Effect on Serum Gal-3 and CTRP9 Expression[J].Journal of Medical Information,2023,36(23):103-106.[doi:10.3969/j.issn.1006-1959.2023.23.026]
点击复制

阿加曲班治疗急性缺血性卒中的疗效及对血清Gal-3、CTRP9表达的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年23期
页码:
103-106
栏目:
论著
出版日期:
2023-12-01

文章信息/Info

Title:
Efficacy of Argatroban in the Treatment of Acute Ischemic Stroke and its Effect on Serum Gal-3 and CTRP9 Expression
文章编号:
1006-1959（2023）23-0103-04
作者:
胡绍福; 朱 江; 张志敏; 等
（承德医学院附属医院神经内科，河北 承德 067000）
Author(s):
HU Shao-fu; ZHU Jiang; ZHANG Zhi-min; et al.
(Department of Neurology,Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,China)
关键词:
阿加曲班; 急性缺血性卒中; Gal-3; CTRP9
Keywords:
Argatroban; Acute ischemic stroke; Gal-3; CTRP9
分类号:
R743.3
DOI:
10.3969/j.issn.1006-1959.2023.23.026
文献标志码:
A
摘要:
目的 探讨阿加曲班治疗急性缺血性卒中（AIS）的疗效及对血清半乳糖凝集素-3（Gal-3）、C1q/肿瘤坏死因子相关蛋白9（CTRP9）表达的影响。方法 选取2021年11月-2022年7月承德医学院附属医院收治的AIS患者120例作为研究对象。按照随机数字表法分为治疗组、对照组，各60例。对照组行常规治疗，治疗组在对照组治疗基础上联合阿加曲班治疗。比较两组病情严重程度、血清Gal-3和CTRP9水平及预后情况。结果 两组治疗后NIHSS评分低于治疗前（P＜0.05），但组间比较，差异无统计学意义（P＞0.05）；两组治疗后Gal-3水平低于治疗前，CTRP9水平高于治疗前，且治疗组Gal-3水平低于对照组，CTRP9水平高于对照组（P＜0.05）；治疗组90 d后mRS优于对照组（P＜0.05）。结论 阿加曲班治疗AIS可能通过调控Gal-3、CTRP9水平变化改善其神经功能缺损及预后。
Abstract:
Objective To investigate the efficacy of argatroban in the treatment of acute ischemic stroke (AIS) and its effect on the expression of serum galectin-3 (Gal-3) and C1q/tumor necrosis factor-related protein 9 (CTRP9).Methods A total of 120 AIS patients admitted to the Affiliated Hospital of Chengde Medical University from November 2021 to July 2022 were selected as the study subjects. According to the random number table method, they were divided into treatment group and control group, with 60 patients in each group. The control group was treated with routine treatment, and the treatment group was treated with argatroban on the basis of the control group. The severity of the disease, serum Gal-3 and CTRP9 levels and prognosis were compared.Results The NIHSS score of the two groups after treatment was lower than that before treatment (P<0.05), but there was no significant difference between the two groups (P>0.05). After treatment, the level of Gal-3 in the two groups was lower than that before treatment, and the level of CTRP9 was higher than that before treatment, while the level of Gal-3 in the treatment group was lower than that in the control group, and the level of CTRP9 was higher than that in the control group (P<0.05). The mRS after 90 days of the treatment group was better than that of the control group(P<0.05).Conclusion Argatroban may improve the neurological deficit and prognosis of AIS patients by regulating the changes of Gal-3 and CTRP9 levels.

参考文献/References:

[1]From the American Association of Neurological Surgeons (AANS),American Society of Neuroradiology (ASNR),Cardiovascular and Interventional Radiology Society of Europe (CIRSE),et al.Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke[J].Int J Stroke,2018,13(6):612-632.[2]Powers WJ,Rabinstein AA,Ackerson T,et al.Guidelines for the Early Management of Patients With Acute Ischemic Stroke:2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke:A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J].Stroke,2019,50(12):e344-e418.[3]Tsivgoulis G,Zand R,Katsanos AH,et al.Risk of Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis in Patients With Acute Ischemic Stroke and High Cerebral Microbleed Burden:A Meta-analysis[J].JAMA Neurol,2016,73(6):675-683.[4]Chen L,Cao S,Yang J.Argatroban plus aspirin versus aspirin in acute ischemic stroke[J].Neurol Res,2018,40(10):862-867.[5]Lyden P,Pereira B,Chen B,et al.Direct thrombin inhibitor argatroban reduces stroke damage in 2 different models[J].Stroke,2014,45(3):896-899.[6]Sayed A,Munir M,Nabet MS,et al.Galectin-3:A Novel Marker for the Prediction of Stroke Incidence and Clinical Prognosis[J].Mediators Inflamm,2022,2022:2924773.[7]Ramakrishnan P.Could Galectin-3 be a key player in the etiology of neuromyelitis optica spectrum disorder?[J].Med Hypotheses,2021,146:110450.[8]Dong R,Zhang M,Hu Q,et al.Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)[J].Int J Mol Med,2018,41(2):599-614.[9]Appari M,Breitbart A,Brandes F,et al.C1q-TNF-Related Protein-9 Promotes Cardiac Hypertrophy and Failure[J].Circ Res,2017,120(1):66-77.[10]Su H,Yuan Y,Wang XM,et al.Inhibition of CTRP9,a novel and cardiac-abundantly expressed cell survival molecule,by TNFα-initiated oxidative signaling contributes to exacerbated cardiac injury in diabetic mice[J].Basic Res Cardiol,2013,108(1):315.[11]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志,2015,48(4):246-257.[12]Klijn CJ,Paciaroni M,Berge E,et al.Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation:A European Stroke Organisation guideline[J].Eur Stroke J,2019,4(3):198-223.[13]Li G,Fan RM,Chen JL,et al.Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage[J].Clin Exp Immunol,2014,175(2):285-295.[14]Oguro H,Mitaki S,Takayoshi H,et al.Retrospective Analysis of Argatroban in 353 Patients with Acute Noncardioembolic Stroke[J].J Stroke Cerebrovasc Dis,2018,27(8):2175-2181.[15]Hara A,Niwa M,Noguchi K,et al.Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases[J].Biomolecules,2020,10(3):389.[16]Papaspyridonos M,Mcneill E,De Bono JP,et al.Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction[J].Arterioscler Thromb Vasc Biol,2008,28(3):433-440.[17]Chen X,Lin J,Hu T,et al.Galectin-3 exacerbates ox-LDL-mediated endothelial injury by inducing inflammation via integrin β1-RhoA-JNK signaling activation[J].J Cell Physiol,2019,234(7):10990-11000.[18]Wong GW,Krawczyk SA,Kitidis-Mitrokostas C,et al.Identification and characterization of CTRP9,a novel secreted glycoprotein,from adipose tissue that reduces serum glucose in mice and forms heterotrimers with adiponectin[J].FASEB J,2009,23(1):241-258.[19]Yang G,Song Q,Sun C,et al.Ctrp9 and adiponectin receptors in Nile tilapia (Oreochromis niloticus):Molecular cloning,tissue distribution and effects on reproductive genes[J].Gen Comp Endocrinol,2018,265:160-173.[20]Yang Y,Li Y,Ma Z,et al.A brief glimpse at CTRP3 and CTRP9 in lipid metabolism and cardiovascular protection[J].Prog Lipid Res,2016,64:170-177.[21]Shibata R,Ohashi K,Murohara T,et al.The potential of adipokines as therapeutic agents for cardiovascular disease[J].Cytokine Growth Factor Rev,2014,25(4):483-487.[22]Ueki Y,Matsumoto K,Kizaki Y,et al.Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease:placebo-controlled study[J].J Thromb Thrombolysis,1999,8(2):131-137.[23]张亮,程立,刘桂花,等.阿加曲班治疗急性脑梗死对患者血管内皮功能Hcy及炎症状态的影响[J].中国实用神经疾病杂志,2017,20(8):17-19.

相似文献/References:

[1]冯 湧.新一代抗凝血药阿加曲班的临床应用进展[J].医学信息,2018,31(02):43.[doi:10.3969/j.issn.1006-1959.2018.02.015]
　FENG Yong.Progress in Clinical Application of the New Generation Anticoagulant Agatripine[J].Journal of Medical Information,2018,31(23):43.[doi:10.3969/j.issn.1006-1959.2018.02.015]
[2]陈建新.阿加曲班注射液治疗急性脑梗死的疗效及对血清VEGF、GLUT-1水平的影响[J].医学信息,2018,31(19):5.[doi:10.3969/j.issn.1006-1959.2018.19.002]
　CHEN Jian-xin.Effect of Argatroban Injection on Acute Cerebral Infarction and Its Effect on Serum VEGF and GLUT-1 Levels[J].Journal of Medical Information,2018,31(23):5.[doi:10.3969/j.issn.1006-1959.2018.19.002]
[3]钱朝庆,刘 淼,王家平,等.肾病综合征合并肾静脉血栓应用阿加曲班疗效评价[J].医学信息,2018,31(21):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
　QIAN Chao-qing,LIU Miao,WANG Jia-ping,et al.Clinical Efficacy Evaluation of Argatroban in Nephrotic Syndrome with Renal Vein Thrombosis[J].Journal of Medical Information,2018,31(23):135.[doi:10.3969/j.issn.1006-1959.2018.21.038]
[4]王 英,李彤彤,王 燕,等.替罗非班对急性缺血性卒中大鼠PI3K/Akt/eNOS通路及神经损伤的影响[J].医学信息,2022,35(07):66.[doi:10.3969/j.issn.1006-1959.2022.07.016]
　WANG Ying,LI Tong-tong,WANG Yan,et al.Effects of Tirofiban on PI3K/Akt/eNOS Pathway and Nerve Injury in Rats with Acute Ischemic Stroke[J].Journal of Medical Information,2022,35(23):66.[doi:10.3969/j.issn.1006-1959.2022.07.016]
[5]褚春沐.阿加曲班联合阿替普酶静脉溶栓治疗急性脑梗死的效果及对脑血管储备功能的影响[J].医学信息,2022,35(13):133.[doi:10.3969/j.issn.1006-1959.2022.13.031]
　CHU Chun-mu.Effect of Argatroban Combined with Alteplase Intravenous Thrombolysis on Acute Cerebral Infarction and its Effect on Cerebrovascular Reserve Function[J].Journal of Medical Information,2022,35(23):133.[doi:10.3969/j.issn.1006-1959.2022.13.031]
[6]王 杰.阿加曲班对脑梗塞急性期患者血液流变指标及APTT、PT的影响[J].医学信息,2022,35(22):130.[doi:10.3969/j.issn.1006-1959.2022.22.030]
　WANG Jie.Effects of Argatroban on Hemorheology Indexes, APTT and PT in Patients with Acute Cerebral Infarction[J].Journal of Medical Information,2022,35(23):130.[doi:10.3969/j.issn.1006-1959.2022.22.030]
[7]赵东慧,王 楠,杨思远.阿加曲班联合阿替普酶静脉溶栓治疗急性脑梗死的疗效及对脑血管储备功能的影响[J].医学信息,2023,36(13):151.[doi:10.3969/j.issn.1006-1959.2023.13.033]
　ZHAO Dong-hui,WANG Nan,YANG Si-yuan.Effect of Argatroban Combined with Alteplase Intravenous Thrombolysis on Acute Cerebral Infarction and its Effect on Cerebrovascular Reserve Function[J].Journal of Medical Information,2023,36(23):151.[doi:10.3969/j.issn.1006-1959.2023.13.033]

更新日期/Last Update: 1900-01-01